During the past decade, UMC Utrecht, Van Creveldkliniek conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "UMC Utrecht, Van Creveldkliniek" are "Hemophilia B" (3 trials) and "Pyruvate Kinase Deficiency" (1 trials). Many other conditions were trialed in "UMC Utrecht, Van Creveldkliniek" in a lesser frequency.

Most popular intervention types in "UMC Utrecht, Van Creveldkliniek" are "Drug" (2 trials), "Genetic" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "AAV5-hFIX" (1 trials), "AAV5-hFIXco-Padua" (1 trials), "AG-348" (1 trials), "Factor IX (FIX)" (1 trials) and "human coagulation Factor IX" (1 trials). Other intervention names were less common.

The vast majority of trials in "UMC Utrecht, Van Creveldkliniek" are 2 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "UMC Utrecht, Van Creveldkliniek". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in UMC Utrecht, Van Creveldkliniek, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in UMC Utrecht, Van Creveldkliniek, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".